← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Globeimmune, Inc.
Louisville, CO
$5,684,394
Total funding
4
Grants
Funding over time
peak $1M · FY2006–16$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$5,684,394 · 4
By mechanism
R01$4,000,000 · 1
R44$995,686 · 1
U01$588,698 · 1
R43$100,010 · 1
Investigators at Globeimmune, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Recombinant yeast vaccines for sensitive and drug-resistant M. tuberculosis$1,000,000
R01 · FY2013 · AI
Recombinant yeast vaccines for sensitive and drug-resistant M. tuberculosis$1,000,000
R01 · FY2016 · AI
Recombinant yeast vaccines for sensitive and drug-resistant M. tuberculosis$1,000,000
R01 · FY2015 · AI
Recombinant yeast vaccines for sensitive and drug-resistant M. tuberculosis$1,000,000
R01 · FY2014 · AI
FAS LIGAND AS AN IMMUNOSUPPRESSIVE AGENT$497,843
R44 · FY2000 · AI
FAS LIGAND AS AN IMMUNOSUPPRESSIVE AGENT$497,843
R44 · FY2001 · AI
Development of whole yeast-based hepatitis C vaccines and Immunotherapeutics$298,325
U01 · FY2006 · AI
Development of whole yeast-based hepatitis C vaccines and Immunotherapeutics$290,373
U01 · FY2007 · AI
USE OF FAS LIGAND TO SUPPRESS ARTHRITIS$100,010
R43 · FY2001 · AI